Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Terlipressin + Noradrenaline in Cirrhosis with Septic Shock
NCT02468063Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2015
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Mean Arterial Pressure at 6 hours. Started May 2015; status: completed.
02
Drugs
terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02468063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468063.